{"nctId":"NCT03334253","briefTitle":"Low-Dose Atropine for Treatment of Myopia","startDateStruct":{"date":"2018-06-01","type":"ACTUAL"},"conditions":["Myopia"],"count":200,"armGroups":[{"label":"Atropine Group","type":"EXPERIMENTAL","interventionNames":["Drug: Atropine"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo Eyedrops"]}],"interventions":[{"name":"Atropine","otherNames":["Low-Dose Atropine"]},{"name":"Placebo Eyedrops","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 5 years to \\<13 years at time of enrollment. Children within 4 weeks of their 13th birthday are not eligible.\n* Refractive error meeting the following by cycloplegic autorefraction:\n\n  * Myopia -1.00D to -6.00D spherical equivalent (SE) in both eyes\n  * Astigmatism \\<=1.50D in both eyes\n  * Anisometropia \\<1.00D SE\n* Gestational age â‰¥ 32 weeks.\n* Birth weight \\>1500g.\n* Parent understands the protocol and is willing to accept randomization to atropine or placebo.\n* Is willing to participate in a 2 to 4 week run-in phase using daily artificial tear eyedrops.\n* Able to return in 2 to 4 weeks for possible randomization.\n* Parent has a phone (or access to phone) and is willing to be contacted by Investigator's site staff.\n* Relocation outside of the area of an active PEDIG site within next 32 months is not anticipated.\n\nExclusion Criteria:\n\n* Current or previous myopia treatment with atropine, pirenzepine or other anti-muscarinic agent.\n* Current or previous use of bifocals, progressive-addition lenses, or multi-focal contact lenses.\n* Current or previous use of orthoK, rigid gas permeable, or other contact lenses being used to reduce myopia progression.\n* Known atropine allergy.\n* Abnormality of the cornea, lens, central retina, iris or ciliary body.\n* Current or prior history of manifest strabismus, amblyopia, or nystagmus.\n* Prior eyelid, strabismus, intraocular, or refractive surgery.\n* Down syndrome or cerebral palsy.\n* Females who are pregnant, lactating, or intending to become pregnant within the next 30 months.\n\n  * A negative urine pregnancy test will be required for all females who have experienced menarche.","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"12 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Group Comparison of Change in Spherical Equivalent Refractive Error.","description":"The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison).\n\nThe mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis.\n\nThe treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent","description":"Treatment group comparison of change from baseline to 30 months in spherical equivalent in each eye as measured by a masked examiner using cycloplegic autorefraction (off-treatment comparison). Calculated based on the model estimates at 24 months.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":125},"commonTop":["Eye Irritiation","Photophobia","Vision Blurred","Allergic Conjunctivitis","Ocular Discomfort"]}}}